Media stories about Thoratec (NASDAQ:THOR) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Thoratec earned a daily sentiment score of 0.00 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 46.1111340966783 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Thoratec (THOR) remained flat at $63.50 during midday trading on Friday. The stock’s 50-day moving average is $63.03 and its 200 day moving average is $51.62. Thoratec has a 52 week low of $25.04 and a 52 week high of $63.51.
Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company’s products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD).
Receive News & Ratings for Thoratec Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thoratec Co. and related companies with MarketBeat.com's FREE daily email newsletter.